Acarix

Acarix EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Acarix (ACARIX.ST) as of Nov 12, 2026 is -48.01 M SEK. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -66.37 M SEK — a change of -27.66% (higher).

EBITDA

-48.01 MSEK

YoY

-27.66%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Acarix is 2025 -48.01 M SEK. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Acarix was 2024 -66.37 M SEK. It decreases by -27.66% higher compared to the previous year.

The Acarix EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-42.52 M SEK
Jan 1, 2019
-46.44 M SEK
Jan 1, 2020
-41.44 M SEK
Jan 1, 2021
-51.70 M SEK
Jan 1, 2022
-76.84 M SEK
Jan 1, 2023
-77.55 M SEK
Jan 1, 2024
-66.37 M SEK
Jan 1, 2025
-48.01 M SEK
The Acarix EBITDA history
YEAREBITDAYoY
-48.01 MSEK-27.66%
-66.37 MSEK-14.42%
-77.55 MSEK+0.93%
-76.84 MSEK+48.63%
-51.70 MSEK+24.74%
-41.44 MSEK-10.76%
-46.44 MSEK+9.22%
-42.52 MSEK+38.32%
-30.74 MSEK+14.59%
-26.83 MSEK+74.47%
-15.38 MSEK-35.90%
-23.99 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acarix Stock analysis

What does Acarix do? Acarix AB generates revenue through the sale of its primary medical device, the CADScor System, which utilizes phonocardiography for coronary artery disease monitoring. The system is designed for use by physicians, nurses, and laboratory technicians in clinical settings, featuring a chest patch with a recording head positioned at the fourth left intercostal space and a sensor on the sternum. Patients undergo a two-minute heart sound recording guided by audio cues and display instructions, after which the CAD-score is calculated and displayed for diagnostic purposes. The company's business model relies on direct sales of the CADScor System to healthcare providers, including hospitals and diagnostic laboratories, where the device is used for non-invasive rule-out diagnosis of coronary artery disease. The system's unique phonocardiography technique and algorithm-based scoring provide a streamlined diagnostic process, reducing the need for more invasive procedures and appealing to medical professionals seeking efficient diagnostic tools. Acarix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acarix stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Acarix is -48.01 M SEK in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Acarix changed from -66.37 M SEK to -48.01 M SEK, representing a -27.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Acarix since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Acarix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Acarix

All Key Metrics — Acarix